NL301176I2 - Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan - Google Patents

Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan

Info

Publication number: NL301176I2
Authority: NL; Netherlands
Prior art keywords: tepotinib; salts; pharmaceutically acceptable; acceptable solvates; solvates
Prior art date: 2007-07-12

Application number

NL301176C

Other languages

English (en)

Other versions

NL301176I1 (nl

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-12

Filing date

2022-05-30

Publication date

2022-11-03

2022-05-30 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2022-06-01 Publication of NL301176I1 publication Critical patent/NL301176I1/nl

2022-11-03 Publication of NL301176I2 publication Critical patent/NL301176I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Inorganic Chemistry (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)

NL301176C 2007-07-12 2022-05-30 Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan NL301176I2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102007032507A DE102007032507A1 (de)	2007-07-12	2007-07-12	Pyridazinonderivate
PCT/EP2008/003473 WO2009006959A1 (de)	2007-07-12	2008-04-29	Pyridazinonderivate

Publications (2)

Publication Number	Publication Date
NL301176I1 NL301176I1 (nl)	2022-06-01
NL301176I2 true NL301176I2 (nl)	2022-11-03

Family

ID=39638671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301176C NL301176I2 (nl)	2007-07-12	2022-05-30	Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan

Country Status (36)

Country	Link
US (8)	US8580781B2 (nl)
EP (3)	EP2164843B1 (nl)
JP (2)	JP5426543B2 (nl)
KR (2)	KR101553418B1 (nl)
CN (2)	CN101743241B (nl)
AR (2)	AR066543A1 (nl)
AU (2)	AU2008274670B2 (nl)
BR (2)	BRPI0814616B1 (nl)
CA (2)	CA2693600C (nl)
CL (1)	CL2008001392A1 (nl)
CO (2)	CO6170360A2 (nl)
CY (4)	CY1113137T1 (nl)
DE (1)	DE102007032507A1 (nl)
DK (3)	DK2754660T3 (nl)
EA (2)	EA016782B1 (nl)
EC (2)	ECSP109953A (nl)
ES (3)	ES2614283T3 (nl)
FR (1)	FR22C1024I2 (nl)
HK (2)	HK1142891A1 (nl)
HR (3)	HRP20120661T1 (nl)
HU (2)	HUE030519T2 (nl)
IL (2)	IL203094A (nl)
LT (2)	LT2754660T (nl)
MY (2)	MY153727A (nl)
NL (1)	NL301176I2 (nl)
NO (1)	NO2022015I1 (nl)
NZ (1)	NZ583187A (nl)
PE (1)	PE20090287A1 (nl)
PL (3)	PL2164843T3 (nl)
PT (3)	PT2164843E (nl)
SG (1)	SG183739A1 (nl)
SI (3)	SI2754660T1 (nl)
TW (1)	TWI501768B (nl)
UA (2)	UA99621C2 (nl)
WO (2)	WO2009006959A1 (nl)
ZA (1)	ZA201001023B (nl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007026341A1 (de)	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
DE102007038957A1 (de) *	2007-08-17	2009-02-19	Merck Patent Gmbh	6-Thioxo-pyridazinderivate
DE102007041115A1 (de) *	2007-08-30	2009-03-05	Merck Patent Gmbh	Thiadiazinonderivate
DE102007061963A1 (de)	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
DE102008019907A1 (de)	2008-04-21	2009-10-22	Merck Patent Gmbh	Pyridazinonderivate
DE102008028905A1 (de)	2008-06-18	2009-12-24	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008037790A1 (de) *	2008-08-14	2010-02-18	Merck Patent Gmbh	Bicyclische Triazolderivate
AU2009331990B2 (en) *	2008-12-22	2016-04-14	Merck Patent Gmbh	Novel polymorphic forms of 6-(1-methyl-1H-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2H-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
DE102008062826A1 (de) *	2008-12-23	2010-07-01	Merck Patent Gmbh	Pyridazinonderivate
DE102009003954A1 (de) *	2009-01-07	2010-07-08	Merck Patent Gmbh	Pyridazinonderivate
KR101829595B1 (ko)	2009-01-08	2018-02-14	메르크 파텐트 게엠베하	3-（1-｛3-［5-（1-메틸-피페리딘-4일메톡시）-피리미딘-2-일］-벤질｝-6-옥소-1,6-디히드로-피리다진-3-일）-벤조니트릴 히드로클로라이드 염의 신규한 다형체 및 이의 제조 방법
EP2221053A1 (de) *	2009-02-20	2010-08-25	Albert-Ludwigs-Universität Freiburg	Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen
US20130315895A1 (en)	2010-07-01	2013-11-28	Takeda Pharmaceutical Company Limited	COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
DE102011101482B4 (de)	2011-05-13	2017-05-11	Thyssenkrupp Presta Aktiengesellschaft	Sensoranordnung für eine drehbare Welle
CN104203243A (zh) *	2012-03-19	2014-12-10	默克专利股份公司	具有抗肿瘤活性的6-氧代-1,6-二氢-哒嗪衍生物与其他抗肿瘤化合物的组合
KR101842645B1 (ko) *	2012-04-12	2018-03-29	한국화학연구원	신규한 히드라진온이 치환된 피리미딘 유도체 및 그의 용도
AU2013329865B2 (en) *	2012-10-11	2018-04-26	Merck Patent Gmbh	Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
HUE035483T2 (hu) *	2012-11-02	2018-05-02	Merck Patent Gmbh	6-oxo-1,6-dihidro-piridazin-származék hepatocelluláris karcinóma (HCC) kezelésében történõ alkalmazásra
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) *	2012-12-21	2016-03-10	ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈＥｐｉｇｅｎｅｔｉｃｓＣｏｒｐ．	ブロモドメイン阻害剤としての新規複素環式化合物
PL2953944T3 (pl) *	2013-02-07	2017-09-29	Merck Patent Gmbh	Pochodne pirydazynonowe-amidowe
ES2661437T3 (es)	2013-06-21	2018-04-02	Zenith Epigenetics Corp.	Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
ES2806135T3 (es)	2013-06-21	2021-02-16	Zenith Epigenetics Ltd	Nuevos inhibidores de bromodominios bicíclicos
EP3027604B1 (en)	2013-07-31	2019-02-20	Zenith Epigenetics Ltd.	Novel quinazolinones as bromodomain inhibitors
CA2927567C (en) *	2013-10-18	2022-04-26	Celgene Quanticel Research, Inc.	Bromodomain inhibitors
AU2014358668B2 (en) *	2013-12-04	2019-10-24	Galmed Research & Development Ltd.	Aramchol salts
KR20160106147A (ko) *	2014-01-07	2016-09-09	메르크 파텐트 게엠베하	항암 활성을 갖는 6-옥소-1,6-디히드로-피리다진 유도체와 게피티닙의 조합
CA2935889C (en) *	2014-01-07	2022-08-16	Merck Patent Gmbh	A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
US9919034B2 (en)	2014-03-28	2018-03-20	Tamir Biotechnology, Inc.	Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
AU2015241247B2 (en) *	2014-04-01	2017-09-14	Merck Sharp & Dohme Llc	Prodrugs of HIV reverse transcriptase inhibitors
US9642794B2 (en) *	2014-08-18	2017-05-09	Tamir Biotechnology, Inc.	Antiviral pharmaceutical for topical administration
US10835598B2 (en)	2014-08-18	2020-11-17	Orgenesis Inc.	Prophylactic protection against viral infections, particularly HIV
US10179125B2 (en)	2014-12-01	2019-01-15	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
EP3227281A4 (en)	2014-12-01	2018-05-30	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
TWI695837B (zh)	2014-12-04	2020-06-11	比利時商健生藥品公司	作為激酶調節劑之三唑並嗒
WO2016091891A1 (en)	2014-12-09	2016-06-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Human monoclonal antibodies against axl
CN106999492B (zh) *	2014-12-11	2020-12-11	默克专利股份公司	具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与喹唑啉衍生物的组合
CA2966449A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Ltd.	Substituted heterocycles as bromodomain inhibitors
CA2970391A1 (en) *	2014-12-12	2016-06-16	Merck Patent Gmbh	Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
CN107406438B (zh)	2014-12-17	2021-05-14	恒翼生物医药科技(上海)有限公司	溴结构域的抑制剂
WO2016135041A1 (en)	2015-02-26	2016-09-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Fusion proteins and antibodies comprising thereof for promoting apoptosis
WO2016192831A1 (en)	2015-05-29	2016-12-08	Merck Patent Gmbh	Compositions of anions and cations with pharmacological activity
CN107920990A (zh)	2015-06-15	2018-04-17	塔米尔生物技术公司	用于治疗眼睛的病毒性感染的药物
PT3533787T (pt)	2016-10-27	2020-11-20	Fujian Cosunter Pharmaceutical Co Ltd	Composto de piridona como inibidor de c-met
MX2019005786A (es) *	2016-11-18	2019-08-26	Merck Sharp & Dohme	Derivados de indazol utiles como inhibidores de diacilglicerido o-aciltransferasa 2.
GB2579747B8 (en)	2017-08-04	2022-10-05	Skyhawk Therapeutics Inc	Methods and compositions for modulating splicing
CN111465602B (zh)	2017-10-17	2023-05-23	帕劳制药有限公司	4-氨基嘧啶化合物的合成
JP7377798B2 (ja)	2017-11-24	2023-11-10	南京明徳新薬研発有限公司	ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物
EP3786155B1 (en) *	2018-04-26	2023-08-16	Fujian Akeylink Biotechnology Co., Ltd.	Crystal form of c-met inhibitor and salt form thereof and preparation method therefor
CN108752322A (zh) *	2018-09-12	2018-11-06	广州新民培林医药科技有限公司	一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用
WO2020097266A1 (en)	2018-11-06	2020-05-14	Edgewise Therapeutics, Inc.	Pyridazinone compounds and uses thereof
MX2021005348A (es)	2018-11-06	2021-08-11	Edgewise Therapeutics Inc	Compuestos de piridazinonas y usos de los mismos.
EP3877367B1 (en)	2018-11-06	2024-05-22	Edgewise Therapeutics, Inc.	Pyridazinone compounds and uses thereof
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
JP7214879B2 (ja) *	2019-02-01	2023-01-30	メッドシャインディスカバリーインコーポレイテッド	ｃ－Ｍｅｔ阻害剤としてのピリミジニルを含むトリシクリル系化合物
JP7603592B2 (ja)	2019-02-05	2024-12-20	スカイホーク・セラピューティクス・インコーポレーテッド	スプライシングを調節するための方法および組成物
EP3920928A4 (en)	2019-02-06	2022-09-28	Skyhawk Therapeutics, Inc.	METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
SG11202109568TA (en) *	2019-03-20	2021-10-28	Goldfinch Bio Inc	Pyridazinones and methods of use thereof
US20220288068A1 (en)	2019-07-10	2022-09-15	Merck Patent Gmbh	Pharmaceutical preparation
CN114174298B (zh) *	2019-08-14	2023-08-01	正大天晴药业集团南京顺欣制药有限公司	哒嗪酮并嘧啶类衍生物及其医药用途
WO2022063869A2 (en)	2020-09-24	2022-03-31	Merck Patent Gmbh	Compounds for the treatment of viral infections
KR102489160B1 (ko) *	2021-05-26	2023-01-18	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
WO2022250350A1 (ko) *	2021-05-26	2022-12-01	주식회사 이노큐어테라퓨틱스	피페리딘디온 유도체
CA3222061A1 (en)	2021-06-04	2022-12-08	Merck Patent Gmbh	Compounds for the treatment of glioblastoma
JP2024540485A (ja) *	2021-11-17	2024-10-31	エッジワイズセラピューティクス，インコーポレイテッド	ピリダジノン化合物およびその使用
CN114394957B (zh) *	2021-12-24	2023-05-09	武汉九州钰民医药科技有限公司	Met抑制剂盐酸特泊替尼的制备方法
WO2024008929A1 (en)	2022-07-08	2024-01-11	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN116496253B (zh) *	2022-08-19	2024-10-11	中国人民解放军军事科学院军事医学研究院	c-MET蛋白靶向降解剂及其医药应用
CN115583939A (zh) *	2022-11-04	2023-01-10	苏州莱安医药化学技术有限公司	一种特泊替尼中间体的合成方法
WO2024112120A1 (ko) *	2022-11-22	2024-05-30	주식회사 이노큐어테라퓨틱스	신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물
WO2024112119A1 (ko) *	2022-11-22	2024-05-30	주식회사 이노큐어테라퓨틱스	cMET 단백질을 분해하는 디그레이더 및 이를 포함하는 약학 조성물
CN116082309B (zh) *	2023-01-04	2023-10-24	广东莱恩医药研究院有限公司	嘧啶衍生物1d228盐酸盐晶型及其制备方法和应用
CN116768868B (zh) *	2023-08-15	2023-12-08	云南省药物研究所	一种哒嗪酮硫代衍生物及其制备方法和应用
CN118084871B (zh) *	2024-04-29	2024-07-09	中国药科大学	一种靶向降解c-Met蛋白的化合物及其制法和应用

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3853946A (en)	1971-11-11	1974-12-10	Hoffmann La Roche	Process for the preparation of aminomethylene malononitrile
JPS5795964A (en)	1980-12-04	1982-06-15	Morishita Seiyaku Kk	Preparation of 2-substituted-3(2h)-pyridazinone derivative
US4397854A (en)	1981-05-14	1983-08-09	Warner-Lambert Company	Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
AU691673B2 (en)	1994-11-14	1998-05-21	Dow Agrosciences Llc	Pyridazinones and their use as fungicides
US5635494A (en)	1995-04-21	1997-06-03	Rohm And Haas Company	Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DE19604388A1 (de)	1996-02-07	1997-08-14	Merck Patent Gmbh	Arylalkyl-diazinone
HUP9901155A3 (en)	1996-02-13	2003-04-28	Astrazeneca Ab	Quinazoline derivatives as vegf inhibitors
AU719327B2 (en)	1996-03-05	2000-05-04	Astrazeneca Ab	4-anilinoquinazoline derivatives
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
JPH10259176A (ja)	1997-03-17	1998-09-29	Japan Tobacco Inc	血管新生阻害作用を有する新規アミド誘導体及びその用途
GB9714249D0 (en)	1997-07-08	1997-09-10	Angiogene Pharm Ltd	Vascular damaging agents
NZ504045A (en)	1997-11-19	2001-06-29	Kowa Co	Pyridazine derivatives with inhibitory action against interleukin-1-beta production
TWI241295B (en)	1998-03-02	2005-10-11	Kowa Co	Pyridazine derivative and medicine containing the same as effect component
GB9900334D0 (en)	1999-01-07	1999-02-24	Angiogene Pharm Ltd	Tricylic vascular damaging agents
GB9900752D0 (en)	1999-01-15	1999-03-03	Angiogene Pharm Ltd	Benzimidazole vascular damaging agents
AUPQ462299A0 (en)	1999-12-13	2000-01-13	Fujisawa Pharmaceutical Co., Ltd.	Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) *	2000-01-25	2001-06-05	Pfizer Inc.	Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
DE10010422A1 (de)	2000-03-03	2001-09-06	Bayer Ag	6-Carboxyphenylpyridazinon-Derivate und ihre Verwendung
EP1289952A1 (en)	2000-05-31	2003-03-12	AstraZeneca AB	Indole derivatives with vascular damaging activity
EP1301498A1 (en)	2000-07-07	2003-04-16	Angiogene Pharmaceuticals Limited	Colchinol derivatives as angiogenesis inhibitors
IL153484A0 (en)	2000-07-07	2003-07-06	Angiogene Pharm Ltd	Colchinol derivatives as angiogenesis inhibitors
CZ2004516A3 (cs) *	2001-10-31	2004-08-18	Merckápatentágmbh	Inhibitor fosfodiesterázy typu @Ź jeho kombinace s jinými drogami a jeho použití
BR0306988A (pt) *	2002-01-18	2004-11-23	Pharmacia Corp	Piridazinonas substituìdas como inibidores de p38
UA77526C2 (en)	2002-06-07	2006-12-15	Sanofi Aventis	Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
EP1572693A1 (en) *	2002-12-20	2005-09-14	Pharmacia Corporation	Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
US7250417B2 (en)	2003-07-02	2007-07-31	Sugen Inc.	Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
US7959919B2 (en) *	2003-11-19	2011-06-14	Novelmed Therapeutics, Inc.	Method of inhibiting factor B-mediated complement activation
US20070043057A1 (en) *	2005-02-09	2007-02-22	Threshold Pharmaceuticals, Inc.	Lonidamine analogs
TW200612918A (en)	2004-07-29	2006-05-01	Threshold Pharmaceuticals Inc	Lonidamine analogs
US20070015771A1 (en) *	2004-07-29	2007-01-18	Threshold Pharmaceuticals, Inc.	Lonidamine analogs
WO2007044796A2 (en)	2005-10-11	2007-04-19	Nps Pharmaceuticals, Inc.	Pyridazinone compounds as calcilytics
DE102005055354A1 (de)	2005-11-21	2007-10-31	Merck Patent Gmbh	Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de)	2005-11-21	2007-10-31	Merck Patent Gmbh	3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
US7728017B2 (en)	2005-11-30	2010-06-01	Vertex Pharmaceuticals Incorporated	Inhibitors of c-Met and uses thereof
DE102005057924A1 (de)	2005-12-05	2007-06-06	Merck Patent Gmbh	Pyridazinonderivate
BRPI0620292B1 (pt)	2005-12-21	2021-08-24	Janssen Pharmaceutica N. V.	Compostos de triazolopiridazinas como moduladores da cinase, composição, uso, combinação e processo de preparo do referido composto
WO2007130383A2 (en)	2006-04-28	2007-11-15	Northwestern University	Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) *	2006-05-11	2007-11-20	Pfizer Prod Inc	Triazoolpyrazinederivaten.
PE20080403A1 (es) *	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) *	2007-06-06	2008-12-11	Merck Patent Gmbh	Benzoxazolonderivate
DE102007032507A1 (de)	2007-07-12	2009-04-02	Merck Patent Gmbh	Pyridazinonderivate
CN101827595B (zh)	2007-10-16	2013-07-24	诺瓦提斯公司	作为神经肽y2受体调节剂的取代的哌嗪和哌啶类
KR20100089090A (ko)	2007-10-25	2010-08-11	아스트라제네카 아베	세포 증식 장애의 치료에 유용한 피리딘 및 피라진 유도체
MX2010004705A (es) *	2007-10-31	2010-05-27	Nissan Chemical Ind Ltd	Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
US8859580B2 (en)	2007-11-16	2014-10-14	Boehringer Ingelheim International Gmbh	Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
DE102007061963A1 (de) *	2007-12-21	2009-06-25	Merck Patent Gmbh	Pyridazinonderivate
WO2009080533A1 (en)	2007-12-21	2009-07-02	F. Hoffmann-La Roche Ag	Heteroaryl derivatives as orexin receptor antagonists
TW200930375A (en)	2007-12-21	2009-07-16	Exelixis Inc	Benzofuropyrimidinones
US8202996B2 (en)	2007-12-21	2012-06-19	Bristol-Myers Squibb Company	Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CL2008003799A1 (es)	2007-12-21	2009-12-18	Synthon Bv	Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
PE20091339A1 (es)	2007-12-21	2009-09-26	Glaxo Group Ltd	Derivados de oxadiazol con actividad sobre receptores s1p1
WO2009081197A1 (en)	2007-12-21	2009-07-02	Astrazeneca Ab	Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
GB0725059D0 (en)	2007-12-21	2008-01-30	Syngenta Participations Ag	Novel pyridazine derivatives
CL2008003785A1 (es)	2007-12-21	2009-10-09	Du Pont	Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
US7816540B2 (en)	2007-12-21	2010-10-19	Hoffmann-La Roche Inc.	Carboxyl- or hydroxyl-substituted benzimidazole derivatives
BRPI0820779B8 (pt)	2007-12-21	2021-05-25	Palau Pharma Sa	compostos derivados de 4-amino-pirimidina, composição farmacêutica, uso e processo para preparação dos referidos compostos
EP2072506A1 (de)	2007-12-21	2009-06-24	Bayer CropScience AG	Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
KR101610607B1 (ko)	2007-12-21	2016-04-07	에프. 호프만-라 로슈 아게	헤테로사이클릭 항바이러스 화합물
CN101538245B (zh) *	2008-03-18	2011-02-16	中国科学院上海药物研究所	一类哒嗪酮类化合物及其制备方法和制备药物的用途
DE102008019907A1 (de) *	2008-04-21	2009-10-22	Merck Patent Gmbh	Pyridazinonderivate
EP2328586A2 (en) *	2008-05-20	2011-06-08	Cephalon, Inc.	Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) *	2008-06-18	2009-12-24	Merck Patent Gmbh	3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
CN102105454A (zh) *	2008-07-25	2011-06-22	贝林格尔.英格海姆国际有限公司	合成1型11β-羟基类固醇脱氢酶的抑制剂
WO2010113986A1 (ja) *	2009-03-30	2010-10-07	住友化学株式会社	ピリダジノン化合物の有害節足動物防除用途
AR082590A1 (es) *	2010-08-12	2012-12-19	Hoffmann La Roche	Inhibidores de la tirosina-quinasa de bruton

2007
- 2007-07-12 DE DE102007032507A patent/DE102007032507A1/de not_active Withdrawn
2008
- 2008-04-29 CA CA2693600A patent/CA2693600C/en active Active
- 2008-04-29 PL PL08758359T patent/PL2164843T3/pl unknown
- 2008-04-29 PT PT87583597T patent/PT2164843E/pt unknown
- 2008-04-29 DK DK14001269.1T patent/DK2754660T3/en active
- 2008-04-29 EP EP08758359.7A patent/EP2164843B1/de active Active
- 2008-04-29 HU HUE14001269A patent/HUE030519T2/en unknown
- 2008-04-29 KR KR1020107002999A patent/KR101553418B1/ko active IP Right Grant
- 2008-04-29 ES ES14001269T patent/ES2614283T3/es active Active
- 2008-04-29 WO PCT/EP2008/003473 patent/WO2009006959A1/de active Application Filing
- 2008-04-29 PL PL14001269T patent/PL2754660T3/pl unknown
- 2008-04-29 CN CN2008800241496A patent/CN101743241B/zh active Active
- 2008-04-29 MY MYPI2010000066A patent/MY153727A/en unknown
- 2008-04-29 UA UAA201000999A patent/UA99621C2/ru unknown
- 2008-04-29 SI SI200831759A patent/SI2754660T1/sl unknown
- 2008-04-29 JP JP2010515355A patent/JP5426543B2/ja active Active
- 2008-04-29 PT PT140012691T patent/PT2754660T/pt unknown
- 2008-04-29 SG SG2012061180A patent/SG183739A1/en unknown
- 2008-04-29 EP EP14001269.1A patent/EP2754660B1/de active Active
- 2008-04-29 EA EA201000093A patent/EA016782B1/ru unknown
- 2008-04-29 DK DK08758359.7T patent/DK2164843T3/en active
- 2008-04-29 BR BRPI0814616-0A patent/BRPI0814616B1/pt active IP Right Grant
- 2008-04-29 AU AU2008274670A patent/AU2008274670B2/en active Active
- 2008-04-29 US US12/668,535 patent/US8580781B2/en active Active
- 2008-04-29 NZ NZ583187A patent/NZ583187A/en unknown
- 2008-04-29 SI SI200831367T patent/SI2164843T1/sl unknown
- 2008-04-29 LT LTEP14001269.1T patent/LT2754660T/lt unknown
- 2008-04-29 ES ES08758359T patent/ES2526352T3/es active Active
- 2008-05-12 CL CL2008001392A patent/CL2008001392A1/es unknown
- 2008-05-12 PE PE2008000825A patent/PE20090287A1/es active IP Right Grant
- 2008-05-13 AR ARP080102013A patent/AR066543A1/es active IP Right Grant
- 2008-05-13 TW TW097117607A patent/TWI501768B/zh active
- 2008-07-04 MY MYPI2010000061A patent/MY163477A/en unknown
- 2008-07-04 UA UAA201001004A patent/UA99833C2/ru unknown
- 2008-07-04 SI SI200830754T patent/SI2164844T1/sl unknown
- 2008-07-04 US US12/668,491 patent/US8329692B2/en active Active
- 2008-07-04 PL PL08773881T patent/PL2164844T3/pl unknown
- 2008-07-04 ES ES08773881T patent/ES2388883T3/es active Active
- 2008-07-04 BR BRPI0813707-2A patent/BRPI0813707B1/pt active IP Right Grant
- 2008-07-04 EA EA201000094A patent/EA017281B1/ru unknown
- 2008-07-04 CN CN2008800230561A patent/CN101687857B/zh active Active
- 2008-07-04 JP JP2010515398A patent/JP5426544B2/ja active Active
- 2008-07-04 CA CA2692867A patent/CA2692867C/en active Active
- 2008-07-04 DK DK08773881.1T patent/DK2164844T3/da active
- 2008-07-04 EP EP08773881A patent/EP2164844B1/de active Active
- 2008-07-04 AU AU2008274534A patent/AU2008274534B2/en active Active
- 2008-07-04 KR KR1020107003000A patent/KR101544624B1/ko active IP Right Grant
- 2008-07-04 WO PCT/EP2008/005508 patent/WO2009007074A1/de active Application Filing
- 2008-07-04 PT PT08773881T patent/PT2164844E/pt unknown
- 2008-07-11 AR ARP080102976A patent/AR067505A1/es active IP Right Grant
2009
- 2009-12-02 CO CO09137749A patent/CO6170360A2/es active IP Right Grant
- 2009-12-03 CO CO09138245A patent/CO6270257A2/es active IP Right Grant
- 2009-12-31 IL IL203094A patent/IL203094A/en active IP Right Grant
- 2009-12-31 IL IL203091A patent/IL203091A/en active IP Right Grant
2010
- 2010-02-09 EC EC2010009953A patent/ECSP109953A/es unknown
- 2010-02-10 EC EC2010009957A patent/ECSP109957A/es unknown
- 2010-02-11 ZA ZA2010/01023A patent/ZA201001023B/en unknown
- 2010-09-28 HK HK10109277.3A patent/HK1142891A1/xx unknown
- 2010-12-15 HK HK10111690.8A patent/HK1145265A1/xx unknown
2012
- 2012-08-03 US US13/565,914 patent/US8658643B2/en active Active
- 2012-08-16 HR HRP20120661AT patent/HRP20120661T1/hr unknown
- 2012-09-13 CY CY20121100840T patent/CY1113137T1/el unknown
2013
- 2013-03-05 US US13/785,580 patent/US8927540B2/en active Active
- 2013-03-05 US US13/785,471 patent/US8921357B2/en active Active
2014
- 2014-01-07 US US14/149,110 patent/US9062029B2/en active Active
- 2014-09-25 US US14/496,746 patent/US9284300B2/en active Active
2015
- 2015-01-12 HR HRP20150031AT patent/HRP20150031T1/hr unknown
- 2015-01-15 CY CY20151100033T patent/CY1115925T1/el unknown
- 2015-01-22 US US14/602,921 patent/US9403799B2/en active Active
2017
- 2017-01-20 HR HRP20170100TT patent/HRP20170100T1/hr unknown
- 2017-01-26 CY CY20171100120T patent/CY1118498T1/el unknown
2022
- 2022-05-13 NO NO2022015C patent/NO2022015I1/no unknown
- 2022-05-20 LT LTPA2022009C patent/LTPA2022009I1/lt unknown
- 2022-05-25 HU HUS2200024C patent/HUS2200024I1/hu unknown
- 2022-05-30 NL NL301176C patent/NL301176I2/nl unknown
- 2022-06-02 FR FR22C1024C patent/FR22C1024I2/fr active Active
- 2022-06-10 CY CY2022017C patent/CY2022017I2/el unknown

Also Published As

Publication number	Publication date
AU2008274670B2 (en)	2013-03-14
SI2754660T1 (sl)	2017-03-31
MY163477A (en)	2017-09-15
AU2008274534B2 (en)	2013-05-30
CN101687857B (zh)	2013-07-17
ZA201001023B (en)	2010-11-24
AU2008274670A1 (en)	2009-01-15
CA2693600C (en)	2015-10-06
AU2008274534A1 (en)	2009-01-15
EA201000094A1 (ru)	2010-06-30
CO6270257A2 (es)	2011-04-20
US20120295908A1 (en)	2012-11-22
EP2164844A1 (de)	2010-03-24
EA016782B1 (ru)	2012-07-30
CY1118498T1 (el)	2017-07-12
CO6170360A2 (es)	2010-06-18
UA99621C2 (en)	2012-09-10
US9062029B2 (en)	2015-06-23
HUE030519T2 (en)	2017-05-29
US8329692B2 (en)	2012-12-11
US8658643B2 (en)	2014-02-25
EA017281B1 (ru)	2012-11-30
ES2526352T3 (es)	2015-01-09
DE102007032507A1 (de)	2009-04-02
NO2022015I1 (no)	2022-05-13
ECSP109957A (es)	2010-03-31
US20130184260A1 (en)	2013-07-18
KR20100031771A (ko)	2010-03-24
BRPI0813707A2 (pt)	2014-12-30
PT2164844E (pt)	2012-08-31
EP2164844B1 (de)	2012-06-27
DK2164843T3 (en)	2014-12-01
DK2754660T3 (en)	2017-02-13
SI2164843T1 (sl)	2015-02-27
ECSP109953A (es)	2010-03-31
US8921357B2 (en)	2014-12-30
AR067505A1 (es)	2009-10-14
US20140128396A1 (en)	2014-05-08
KR20100050504A (ko)	2010-05-13
PE20090287A1 (es)	2009-03-19
DK2164844T3 (da)	2012-08-20
JP2010532774A (ja)	2010-10-14
HK1145265A1 (en)	2011-04-08
KR101553418B1 (ko)	2015-09-15
HUS2200024I1 (hu)	2022-06-28
HK1142891A1 (en)	2010-12-17
EP2754660A1 (de)	2014-07-16
EP2754660B1 (de)	2016-11-02
US20100234354A1 (en)	2010-09-16
HRP20150031T1 (en)	2015-03-13
HRP20120661T1 (hr)	2012-09-30
CL2008001392A1 (es)	2009-01-23
FR22C1024I2 (fr)	2023-03-24
ES2388883T3 (es)	2012-10-19
KR101544624B1 (ko)	2015-08-17
MY153727A (en)	2015-03-13
EP2164843B1 (de)	2014-10-29
PT2754660T (pt)	2017-02-10
TW200906409A (en)	2009-02-16
NL301176I1 (nl)	2022-06-01
IL203094A (en)	2013-08-29
CN101743241A (zh)	2010-06-16
CY2022017I1 (el)	2023-01-05
CY1113137T1 (el)	2016-04-13
UA99833C2 (en)	2012-10-10
PL2164843T3 (pl)	2015-03-31
BRPI0813707B1 (pt)	2022-02-22
ES2614283T3 (es)	2017-05-30
US20150133452A1 (en)	2015-05-14
JP2010532768A (ja)	2010-10-14
CA2693600A1 (en)	2009-01-15
CA2692867A1 (en)	2009-01-15
EA201000093A1 (ru)	2010-06-30
US20150011534A1 (en)	2015-01-08
US9403799B2 (en)	2016-08-02
CY1115925T1 (el)	2017-01-25
US20130184261A1 (en)	2013-07-18
SI2164844T1 (sl)	2012-10-30
CA2692867C (en)	2016-05-24
SG183739A1 (en)	2012-09-27
CN101743241B (zh)	2013-12-25
TWI501768B (zh)	2015-10-01
IL203091A (en)	2013-10-31
US8580781B2 (en)	2013-11-12
PT2164843E (pt)	2014-12-23
US8927540B2 (en)	2015-01-06
WO2009007074A1 (de)	2009-01-15
US9284300B2 (en)	2016-03-15
NZ583187A (en)	2011-10-28
CY2022017I2 (el)	2023-01-05
AR066543A1 (es)	2009-08-26
EP2164843A1 (de)	2010-03-24
CN101687857A (zh)	2010-03-31
BRPI0814616A2 (pt)	2015-01-27
LT2754660T (lt)	2016-12-12
PL2164844T3 (pl)	2012-10-31
LTPA2022009I1 (nl)	2022-06-10
US20100197690A1 (en)	2010-08-05
FR22C1024I1 (fr)	2022-07-22
HRP20170100T1 (hr)	2017-03-24
PL2754660T3 (pl)	2017-05-31
WO2009006959A1 (de)	2009-01-15
JP5426543B2 (ja)	2014-02-26
BRPI0814616B1 (pt)	2022-04-19
JP5426544B2 (ja)	2014-02-26

Publication	Publication Date	Title
NL301176I2 (nl)	2022-11-03	Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
FIC20240039I1 (fi)	2024-11-12	Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NO2022018I1 (no)	2022-05-31	Avacopan samt farmaceutisk acceptable salte deraf
NO2022057I1 (no)	2022-12-13	Capmatinib or a pharmaceutically acceptable salt thereof
NL300998I1 (nl)	2019-07-03	Lusutrombopag of farmaceutisch aanvaardbare zouten of solvaten daarvan
NO2022013I1 (en)	2022-05-06	Finerenone and its salts, solvates and solvates of the salts thereof
NO2017033I2 (no)	2017-07-11	baricitinib og farmasøytisk akseptable salter derav
NL300871I2 (nl)	2017-12-07	ixazomib en farmaceutisch aanvaardbare zouten en esters daarvan, zoals ixazomibcitraat
NO2024053I1 (no)	2024-12-03	aprocitentan eller et farmasøytisk akseptabelt salt derav
NO2016014I2 (no)	2016-08-10	ceritinib eller farmasøytisk akseptable salter derav
NL301214I2 (nl)	2023-04-19	Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
BRPI0813647A2 (pt)	2014-12-23	Piperazinil oxoalquil tetrahidro-beta-carbolinas e análogos relacionados
BRPI0817082A2 (pt)	2015-03-31	Implantes lacrimais e métodos relacionados
DK3092901T3 (da)	2020-05-18	Quinolonanaloger og fremgangsmåder relateret dertil
HK1137027A1 (en)	2010-07-16	Pyrrolo-nitrogenous heterocyclic derivatives and the pharmaceutical use thereof
DK2144905T3 (da)	2013-03-11	Terapeutiske midler
NO20090004A (no)	2009-01-05	Justerbar svenke
DK2035369T3 (da)	2014-10-06	Terapeutiske
DK2195293T3 (da)	2014-02-03	Cyclopropylamidderivater
DK2001556T3 (da)	2014-11-10	Thioninium-forbindelser og anvendelse deraf
EP2019687A4 (en)	2012-02-15	ANTI-STREPTOCOCCAL VACCINE
DK2018158T3 (da)	2013-07-22	Ny racecadotril administrationsform
EP2128154A4 (en)	2011-01-26	BENZIMIDAZOLE COMPOUND AND ITS PHARMACEUTICAL USE
DE602008001981D1 (de)	2010-09-09	Stellung und therapeutische verwendung
GB0606234D0 (en)	2006-05-10	Pharmaceutically acceptable salts and polymorphic forms